General Archives - Page 48 of 2367

1 minute read

QurAlis Grants Lilly Exclusive Global License For QRL-204, A Precision Therapy That Restores UNC13A Function In ALS And FTD

June 3, 12:35 PM

QRL-204 is a splice-switching ASO generated through QurAlis' FlexASO™ Platform; represents Lilly's first program targeting UNC13A in ALS and FTDParties to also collaborate to leverage QurAlis' ALS and ASO

LLY

2 minute read

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?

By Vandana Singh

June 3, 12:11 PM

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of transfusion reduction response.

AGIO

2 minute read

BD Bolsters Portfolio With $4.2B Cash Deal For Edwards Lifesciences’ Critical Care Group: Details

By Shivani Kumaresan

June 3, 12:02 PM

BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition enhances BD's portfolio with advanced AI-enabled monitoring technologies, aiming to improve patient outcomes in critical care settings. The transaction is expected to boost BD's financial performance, delivering immediate accretive benefits and long-term revenue growth.

BDX

1 minute read

Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024

By Benzinga Newsdesk

June 3, 12:02 PM

First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1

CRNX

2 minute read

Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients

By Vandana Singh

June 3, 12:01 PM

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile.

JNJ

2 minute read

Dave Portnoy Announces $30M GameStop Stake, 700K Shares Of AMC And Is Now Eyeing This Stock

By Aaron Bry

June 3, 11:36 AM

Roaring Kitty's stock bet on GameStop sends market into frenzy again. Dave Portnoy discusses investment and AMC's rise as well. Portnoy looks to buy Faraday Future Intelligent Electric.

AMC

2 minute read

Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate

By Vandana Singh

June 3, 11:11 AM

Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study.

GPCR

2 minute read

Tesla Argues New Pay Plan For Musk Would Cost More: Report

By Shivani Kumaresan

June 3, 10:48 AM

Tesla Inc. (NASDAQ: TSLA) defends Elon Musk's $56 billion pay package, stating that a new compensation plan would be costlier.

FDIS

2 minute read

Roaring Kitty’s GameStop Resurgence: Why GME Could Be Poised For More Gains

By Surbhi Jain

June 3, 10:48 AM

Keith Gill's recent social media post disclosed a staggering $116 million position in GameStop — 120,000 call options valued at $65.7 million.

GME

2 minute read

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

By Vandana Singh

June 3, 10:27 AM

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.

MRK